Scandion Oncology announces share purchase by a member of the Board of Directors
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that a member of the Board of Directors has purchased shares in the company.The following share purchase has been reported: Shares purchased Total shareholding Peter Chairman of the Board 2,500 62,065HøngaardAndersen Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management. For further information regarding Scandion Oncology, please contact: Bo Rode Hansen, President &